AbbVie’s upadacitinib demonstrates strong performance in rheumatoid arthritis trial

AbbVie has announced the findings of a new clinical trial that demonstrate the strong performance of its drug upadacitinib in the treatment of rheumatoid arthritis.

Topline results from the phase III SELECT-COMPARE clinical trial have shown that after 12 weeks, upadacitinib was able to meet its primary endpoints in terms of response and clinical remission rates compared to placebo.

All ranked secondary endpoints were also achieved, with the drug showing a superior performance to both placebo and AbbVie's own blockbuster drug Humira when used by patients with moderate to severe rheumatoid arthritis.

Despite the range of available treatments, many patients with rheumatoid arthritis still do not achieve clinical remission or low disease activity targets, meaning there remains a strong demand for new treatment options of this kind.

Dr Michael Severino, executive vice-president for research and development and chief scientific officer of AbbVie, said: "We are excited by these strong results, which add to the body of evidence that support the potential of upadacitinib to be an important treatment option for patients with rheumatoid arthritis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.